ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 181 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $269,397 | -48.3% | 24,118 | -0.9% | 0.00% | 0.0% |
| Q2 2023 | $520,704 | -46.6% | 24,332 | +0.9% | 0.00% | -50.0% |
| Q1 2023 | $975,614 | -14.7% | 24,125 | -1.9% | 0.00% | 0.0% |
| Q4 2022 | $1,143,600 | +3.5% | 24,583 | +15.3% | 0.00% | 0.0% |
| Q3 2022 | $1,105,000 | +13.0% | 21,324 | +2.9% | 0.00% | 0.0% |
| Q2 2022 | $978,000 | -7.3% | 20,721 | +39.5% | 0.00% | 0.0% |
| Q1 2022 | $1,055,000 | -31.7% | 14,849 | -28.1% | 0.00% | 0.0% |
| Q4 2021 | $1,544,000 | -15.5% | 20,665 | -35.8% | 0.00% | -33.3% |
| Q3 2021 | $1,827,000 | +23.4% | 32,193 | -4.4% | 0.00% | +50.0% |
| Q2 2021 | $1,480,000 | -65.0% | 33,688 | -61.0% | 0.00% | -71.4% |
| Q1 2021 | $4,234,000 | -2.5% | 86,377 | -16.5% | 0.01% | -22.2% |
| Q4 2020 | $4,342,000 | -11.5% | 103,492 | -3.9% | 0.01% | -18.2% |
| Q3 2020 | $4,905,000 | -28.1% | 107,694 | -21.2% | 0.01% | -26.7% |
| Q2 2020 | $6,820,000 | +0.2% | 136,666 | +2.9% | 0.02% | -16.7% |
| Q1 2020 | $6,806,000 | +5.2% | 132,826 | +26.7% | 0.02% | +50.0% |
| Q4 2019 | $6,470,000 | +10.4% | 104,872 | +7.8% | 0.01% | +9.1% |
| Q3 2019 | $5,859,000 | -22.0% | 97,328 | +8.7% | 0.01% | -21.4% |
| Q2 2019 | $7,515,000 | -10.0% | 89,505 | +2.2% | 0.01% | -6.7% |
| Q1 2019 | $8,351,000 | +33.6% | 87,615 | -1.5% | 0.02% | +7.1% |
| Q4 2018 | $6,253,000 | -22.4% | 88,947 | -3.0% | 0.01% | -6.7% |
| Q3 2018 | $8,057,000 | -15.2% | 91,704 | +9.8% | 0.02% | -25.0% |
| Q2 2018 | $9,500,000 | +169.0% | 83,552 | +91.4% | 0.02% | +233.3% |
| Q1 2018 | $3,532,000 | +192.6% | 43,644 | +114.6% | 0.01% | +200.0% |
| Q4 2017 | $1,207,000 | +1945.8% | 20,339 | +1501.5% | 0.00% | – |
| Q3 2017 | $59,000 | -89.0% | 1,270 | -92.7% | 0.00% | -100.0% |
| Q1 2017 | $534,000 | -49.1% | 17,347 | -44.5% | 0.00% | -50.0% |
| Q4 2016 | $1,050,000 | – | 31,272 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |